HB1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Margins And EBITDA ExpansionSustained margin expansion and rising adjusted EBITDA indicate durable operational leverage and pricing power within Fuller’s specialty adhesives portfolio. Higher gross and EBITDA margins provide a structural cushion against input-cost volatility, support reinvestment and margin-accretive M&A, and underpin longer-term profit sustainability.
Diversified Specialty-adhesives Franchise & Global FootprintA diversified B2B franchise across multiple end markets with application-specific formulations and on-site technical support creates sticky customer relationships. This breadth smooths cyclicality, enables pricing by performance, and supports durable revenue streams and cross-selling as customers prioritize reliable supply and product qualification.
Strategic AMS Acquisition Expands Medical Exposure And TAMBuying AMS is a structural move to scale Fuller’s medical adhesives and biosurgical portfolio, accelerating access to higher-margin healthcare end markets. The deal materially enlarges addressable market, creates cross-selling and commercial leverage, and supports a multi-year path to higher combined medical margins and revenue diversification.
Bears Say
Near-term Leverage Spike To ~4x Post-AMSA pro forma leverage increase to ~4x materially constrains financial flexibility and heightens refinancing and covenant risk if macro or execution setbacks occur. Fuller will depend on timely synergy realization and strong cash flow to deleverage, making capital allocation and integration execution critical over the next 24 months.
Weak Cash Conversion And Declining Free Cash FlowSub‑par cash conversion (CFO and FCF under half of reported earnings) reduces the firm’s ability to self-fund investments, pay down debt, or absorb shocks. Persistently weaker FCF raises dependence on external financing, which magnifies leverage risk especially when funding large, strategic acquisitions.
Persistent Raw-material Inflation And Volume PressureOngoing petrochemical supply issues and projected H2 volume declines exert structural pressure on growth and margin sustainability. Even with pricing, extended input inflation and force majeure events can erode demand in consumer-exposed segments and delay margin normalization, stressing execution and working-capital management.
HB1 FAQ
What was H.B. Fuller Company’s price range in the past 12 months?
Currently, no data Available
What is H.B. Fuller Company’s market cap?
H.B. Fuller Company’s market cap is CHF2.40B.
When is H.B. Fuller Company’s upcoming earnings report date?
H.B. Fuller Company’s upcoming earnings report date is Sep 30, 2026 which is in 59 days.
How were H.B. Fuller Company’s earnings last quarter?
H.B. Fuller Company released its earnings results on Jun 24, 2026. The company reported $1.139 earnings per share for the quarter, beating the consensus estimate of $1.128 by $0.011.
Is H.B. Fuller Company overvalued?
According to Wall Street analysts H.B. Fuller Company’s price is currently Undervalued.
Does H.B. Fuller Company pay dividends?
H.B. Fuller Company does not currently pay dividends.
What is H.B. Fuller Company’s EPS estimate?
H.B. Fuller Company’s EPS estimate is 1.19.
How many shares outstanding does H.B. Fuller Company have?
Currently, no data Available
What happened to H.B. Fuller Company’s price movement after its last earnings report?
H.B. Fuller Company reported an EPS of $1.139 in its last earnings report, beating expectations of $1.128. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of H.B. Fuller Company?
Currently, no hedge funds are holding shares in CH:HB1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
H.B. Fuller Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF58.87 (― Upside)
CHF58.87 (― Upside)
Blogger Sentiment
Bullish
CH:HB1 Sentiment 80%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.83%
Trailing 12-Months
Company Description
H.B. Fuller Company
H.B. Fuller Company, together with its subsidiaries, formulates, manufactures, and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives, and other specialty chemical products. It operates through three segments: Hygiene, Health and Consumable Adhesives; Engineering Adhesives; and Building Adhesive Solutions. The Hygiene, Health and Consumable Adhesives segment produces and supplies specialty industrial adhesives, such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven and hygiene, and medical and beauty. The Engineering Adhesives segment produces and supplies high performance industrial adhesives comprising reactive, light cure, two-part liquids, polyurethane, silicone, film, and fast cure products to the durable assembly, performance wood and textile, transportation, electronics, clean energy, aerospace and defense, appliance, heavy machinery, and insulating glass markets. The Construction Adhesives segment provides products used for commercial roofing, heating, ventilation, and air conditioning and insulation applications, as well as caulks and sealants for the consumer market and professional trade. The company sells its products directly to customers, as well as through distributors and retailers in North America, Latin America, Europe, India, the Middle East, Africa, and the Asia Pacific. H.B. Fuller Company was founded in 1887 and is headquartered in Saint Paul, Minnesota.
HB1 Company Deck
HB1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company delivered solid Q2 results with revenue, EBITDA, margin and EPS expansion, record second‑quarter cash flow, and clear operational execution amid supply disruptions. Management provided improved full‑year guidance and outlined a strategic, scale‑enhancing acquisition (AMS) with sizable identified synergies that should accelerate medical exposure and margin expansion. Offsetting these positives are continued raw material inflation and supply‑chain disruption, near‑term volume weakness (mid‑single digit expected in H2), and a meaningful near‑term increase in leverage (pro forma ~4x) that prompted investor pushback and share price weakness. Management expects to deleverage within two years and to realize synergies over 2028–2030, but these bring execution and timing risk.View all CH:HB1 earnings summariesHB1 Stock 12 Month Forecast
All Analysts
Top Analysts










